Read more

May 31, 2022
1 min read
Save

HHS announces Medicare premium increase for Aduhelm will be adjusted in 2023

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

HHS announced that Medicare Part B premiums paid in 2022 should be lowered in 2023 to account for an overestimate in costs related to inclusion of Aduhelm within the Medicare program for reimbursement.

According to an HHS release, legal and operational hurdles prevented adjustments in Medicare premiums this year, prompting reductions in costs attributable to Aduhelm (aducanumab, Biogen) into Medicare premiums in 2023 to lower Part B premiums paid by Medicare beneficiaries.

Pill bottles
Source: Adobe Stock.

The decision to lower premium payments arose after HHS received a report from CMS, which concluded that cost savings from lower-than-expected Medicare Part B spending on Aduhelm can be passed along to beneficiaries by lowering the 2023 Part B premium.

“We had hoped to achieve this sooner, but CMS explains that the options to accomplish this would not be feasible,” HHS Secretary Xavier Becerra said in the release. “CMS and HHS are committed to lowering health care costs — so we look forward to seeing this Medicare premium adjustment across the finish line to ensure seniors get their cost-savings in 2023.”